Functionally, this means that an immunogenic tumor, which has abundant type I and II IFN present within the microenvironment, will express PD-L1 and evade T-lymphocyte mediated killing of tumor cells (so called “adaptive resistance”). The gene discussed is SGCG; the disease is neoplasm.